Metavista3D: Haben Sie unseren Hinweis genutzt? | Am Mittwoch hatten wir im Express-Service sinngemäß geschrieben, dass der Widerstand zum Redaktionsschluss überwunden ist und Kurse bis 2,00 Euro möglich sind. Wir hatten noch einmal darauf hingewiesen... ► Artikel lesen |
EQS-News: Metavista3D, Inc.: Metavista3D Beauftragt Bereitstellung Von Räumlichen Anzeigen | EQS-News: Metavista3D, Inc.
/ Schlagwort(e): Miscellaneous
Metavista3D Beauftragt Bereitstellung Von Räumlichen Anzeigen
08.08.2025 / 03:00 CET/CEST
Für den Inhalt der... ► Artikel lesen |
Metavista3D, Inc.: Metavista3D Engaged to Provide Spatial Display Demonstration Units | Vancouver, British Columbia--(Newsfile Corp. - August 7, 2025) - Metavista3D Inc. (TSXV: DDD) (FSE: E3T) ("Metavista3D" or the "Company") announces that it currently has binding arrangements with customers... ► Artikel lesen |
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results | Revenues increased 18% compared to same period last yearU.S. revenue increased 57% compared to same period last yearNet loss per share decreased 43% compared to same period last year BOULDER, COLORADO... ► Artikel lesen |
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen |
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen |